CUE-101 + Pembrolizumab
Phase 2Recruiting 0 watching 0 views this week⚡ Active
44
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Head and Neck Squamous Cell Carcinoma
Conditions
Head and Neck Squamous Cell Carcinoma, HPV Positive Oropharyngeal Squamous Cell Carcinoma, New Diagnosis Tumor, Locally Advanced
Trial Timeline
Feb 1, 2026 → Feb 1, 2031
NCT ID
NCT07172256About CUE-101 + Pembrolizumab
CUE-101 + Pembrolizumab is a phase 2 stage product being developed by Cue Biopharma for Head and Neck Squamous Cell Carcinoma. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07172256. Target conditions include Head and Neck Squamous Cell Carcinoma, HPV Positive Oropharyngeal Squamous Cell Carcinoma, New Diagnosis Tumor.
Hype Score Breakdown
Clinical
17
Activity
12
Company
2
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07172256 | Phase 2 | Recruiting |
Competing Products
20 competing products in Head and Neck Squamous Cell Carcinoma